ADIENNE Pharma signs manufacturing deal with Selexis

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

- Advertisement -

ADIENNE Pharma & Biotech has signed a service agreement with Selexis for the development of a manufacturing cell line for one of the ADIENNE’s orphan drugs.

Selexis CEO Igor Fisch said, “Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform(TM) is an important step in advancing ADIENNE’s project to the clinic.”

ADIENNE Pharma & Biotech founder and CEO Antonio Francesco Di Naro said Selexis expertise will be an added value for the company’s molecule.

Selexis is a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.

Our 2026 Media Pack offers integrated solutions to reach your audience:

Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Your Laboratory Freezer Just Alarmed: A Lab Manager’s Response Plan to…

Regulatory Strategy for Early-Stage Biotech and Medtech Companies

BioNTech and Gilead Partner for Pumitamig Clinical Trial

Cencora to Acquire American Oncology Network in $2.4 Billion Deal

Merck Acquires Silence Therapeutics for $1.3 Billion

RABS upgrade for Inibsa, Achieving Annex 1 compliance together

Milestone Leadership in Action: Behaviors That Build Winning Biotech Companies

Beyond the Digital Foundation: How Connected Intelligence Is Redefining Pharma Production

India’s ₹2,333 Crore Weight-Loss Drug Story: Mounjaro, Semaglutide and the Next…

eschbach Launches New Digital Leader Standard Work Capability for Pharma Process…

Pharma Leaders to Examine What Comes After AI Pilots at Digital…

Oliver Healthcare Packaging Highlights Material Selection for Pharmaceutical Drug Protection

Thermo Fisher Scientific Introduces E-Gel Power Snap Lite System for Simplified…

UCB Reports New EADV Data on Bimekizumab Treatment in HS

CPHI Sustainability Summit Targets Practical Pharma Action

ADIENNE Pharma signs manufacturing deal with Selexis

Equipment Retrofit Planning Improving Pharmaceutical Production Continuity

Sterile Area Segregation Improving Aseptic Manufacturing Control

Annex 1 Implementation Strengthening Pharmaceutical Contamination Control

Sterile Area Segregation Improving Aseptic Manufacturing...

Annex 1 Implementation Strengthening Pharmaceutical Contamination...

Glove Port Ergonomics Improving Accessibility in...

RABS Integration Improving Contamination Control in...

BioNTech and Gilead Partner for Pumitamig...

Cencora to Acquire American Oncology Network...

Pharma Leaders to Examine What Comes...

Oliver Healthcare Packaging Highlights Material Selection...

Equipment Retrofit Planning Improving Pharmaceutical Production Continuity

Sterile Area Segregation Improving Aseptic Manufacturing Control

Annex 1 Implementation Strengthening Pharmaceutical Contamination Control

Glove Port Ergonomics Improving Accessibility in Aseptic Filling Lines

About us

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Your Laboratory Freezer Just Alarmed: A Lab Manager’s Response Plan to...

Equipment Retrofit Planning Improving Pharmaceutical Production Continuity